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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to “native 
chicory inulin” and maintenance of normal defecation by increasing stool 
frequency pursuant to Article 13.5 of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from BENEO-Orafti S.A., submitted pursuant to Article 13.5 of Regulation (EC) No 
1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to “native 
chicory inulin” and maintenance of normal defecation by increasing stool frequency. The food constituent that is 
a subject of a claim is “native chicory inulin”. The Panel considers that “native chicory inulin”, a non-
fractionated mixture of monosaccharides (< 10%), disaccharides, inulin-type fructans and inulin extracted from 
chicory, with a mean DP ≥ 9, is sufficiently characterised in relation to the claimed effect. The Panel considers 
that maintenance of normal defecation by increasing stool frequency (provided that it does not result in 
diarrhoea) is a beneficial physiological effect. Six studies involving 86 subjects consistently showed that 
consumption of “native chicory inulin” at an amount of at least 12 g/day increases stool frequency. The Panel 
also notes the plausible mechanisms by which inulin and inulin-type fructans in “native chicory inulin” could 
exert the claimed effect. The Panel concludes that a cause and effect relationship has been established between 
the consumption of “native chicory inulin” and maintenance of normal defecation by increasing stool frequency. 
The following wording reflects the scientific evidence: “Chicory inulin contributes to maintenance of normal 
defecation by increasing stool frequency”. In order to obtain the claimed effect, 12 g of “native chicory inulin” 
should be consumed daily. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from BENEO-Orafti, submitted pursuant to Article 13.5 of Regulation (EC) 
No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to “native chicory inulin” and maintenance of normal defecation by increasing stool frequency. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data.  
The food constituent that is the subject of the health claim is “native chicory inulin”. The Panel 
considers that “native chicory inulin”, a non-fractionated mixture of monosaccharides (< 10%), 
disaccharides, inulin-type fructans and inulin extracted from chicory, with a mean DP ≥ 9, is 
sufficiently characterised in relation to the claimed effect. 
The claimed effect proposed by the applicant is “improves bowel function”. The target population 
proposed by the applicant is the general population. The Panel considers that maintenance of normal 
defecation by increasing stool frequency (provided that it does not result in diarrhoea) is a beneficial 
physiological effect. 
Six out of eight human studies provided reported an increase in stool frequency with the consumption 
of “native chicory inulins” or chicory inulin. In these studies, the doses of “native chicory inulin” used 
ranged from 12 to 40 g/day and the dose of chicory inulin, which was used in one study, was 15 g/day. 
In two studies (three arms), administration of chicory inulin at doses from 5 to 8 g/day did not affect 
stool frequency. No adverse effects have been reported in any of these studies.  
In weighing the evidence, the Panel took into account that six studies involving 86 subjects 
consistently showed that consumption of at least 12 g/day “native chicory inulin” increases stool 
frequency. The Panel also notes the plausible mechanisms by which inulin and inulin-type fructans in 
“native chicory inulin” could exert the claimed effect. 
On the basis of data presented, the Panel concludes that a cause and effect relationship has been 
established between the consumption of “native chicory inulin”, a non-fractionated mixture of 
monosaccharides (< 10%), disaccharides, inulin-type fructans and inulin extracted from chicory, with 
a mean DP ≥ 9, and maintenance of normal defecation by increasing stool frequency. The Panel could 
have reached the conclusion that “native chicory inulin” contributes to the maintenance of normal 
defecation by increasing stool frequency without the study identified as proprietary by the applicant. 
However, this study was used to establish the conditions of use for this claim. 
The following wording reflects the scientific evidence: “Chicory inulin contributes to maintenance of 
normal defecation by increasing stool frequency”. In order to obtain the claimed effect, 12 g “native 
chicory inulin” should be consumed daily. The target population is the general population. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 06/06/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 The scientific evaluation procedure started on 02/07/2014. 
 On 08/07/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the clock 
was stopped on 11/07/2014, in compliance with Art. 18(3) of Regulation (EC) No 1924/2006. 
 On 25/07/2014, EFSA received the applicant’s reply and the clock was restarted. 
 On 15/10/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the clock 
was stopped on 23/10/2014, in compliance with Art. 18(3) of Regulation (EC) No 1924/2006. 
 On 04/11/2014, EFSA received the applicant’s reply and the clock was restarted. 
 During its meeting on 11/12/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to ”native chicory 
inulin” and maintenance of normal defecation by increasing stool frequency.  
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to “native chicory inulin” and maintenance of 
normal defecation by increasing stool frequency. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of “native chicory inulin”, a positive assessment of its safety, nor a decision on whether ”native 
chicory inulin” is, or is not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT  
Applicant’s name and address: BENEO-Orafti S.A., Rue L. Maréchal 1, B-4360 Oreye, Belgium.  
The application contains a request for the protection of proprietary data for unpublished Schulz et al. 
(2012) study report in accordance with Article 21 of Regulation (EC) No 1924/2006.  
Food constituent as stated by the applicant 
According to the applicant, the food for which this health claim is made is Orafti®Inulin. At the 
request of EFSA the applicant clarified that “chicory inulin” constitutes the subject of the health claim. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect refers to the ability of the fully fermentable dietary fibre 
Orafti®Inulin to increase the frequency of bowel movements and thus to improve bowel function. The 
frequency of bowel movements is used as primary outcome measure to assess the claimed effect of an 
improved bowel function. Secondary outcome measures comprise the assessment of stool bulk, stool 
consistency and transit time. Inulin resists hydrolysis and absorption in the human small intestine, but 
reaches the large intestine essentially complete, where it is fermented to short-chain fatty acids, lactate 
and gases by colonic bacteria. This is accompanied by an increase in bacterial cell mass and a higher 
water content of digesta. In this way Orafti®Inulin leads to softer stools and facilitated excretion as 
well as to an enhanced propulsion of colonic contents via chemical and mechanical stimulation of the 
peristaltic reflex and hence an increase in the frequency of bowel movements. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wordings for the health claim: “Orafti®Inulin improves 
bowel function”. Alternative wordings: “Orafti®Inulin improves bowel movements”, “Orafti®Inulin 
contributes to more frequent bowel movements”, “Orafti®Inulin improves/contributes to/maintains 
normal bowel movements”, “Orafti®Inulin contributes to/maintains a normal bowel function”, 
“Orafti®Inulin contributes to/maintains a normal digestive function”, “Orafti®Inulin 
improves/contributes to/maintains regularity”, “Orafti®Inulin imroves/contributes to/maintains bowel 
regularity”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an amount of 12 g Orafti®Inulin daily. The target population proposed is 
the general population. 
ASSESSMENT 
1. Characterisation of the food constituent 
The applicant initially stated that the food constituent that is the subject of the health claim is 
“Orafti®Inulin”. In response to the EFSA’s request for clarification, the applicant explained that 
“chicory inulin” is the food constituent that is the subject of the health claim.   
Chemically, inulin is a linear β(2→1)-fructan with a degree of polymerisation (DP) > 9 which 
typically has a terminal α-glucose (EFSA NDA Panel, 2010). 
Chicory (Chicorium intybus) root is one of the plants with the highest concentration of inulin. “Native 
chicory inulin” is extracted as a non-fractionated mixture of monosaccharides, disaccharides, 
oligosaccharides (inulin-type fructans, DP 3 – 9) and non-starch polysaccharides (inulin, DP > 9). 
Influencing factors for chain length distribution are growth conditions and harvest time as well as 
process technology. 
“Native chicory inulin” and maintenance of normal defecation 
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From the information provided, including the human studies submitted for the scientific substantiation 
of the claim, the Panel notes that this claim relates to “native chicory inulin”, a non-fractionated 
mixture of monosaccharides (< 10%), disaccharides, oligosaccharides (inulin-type fructans) and 
polysaccharides (inulin) extracted from fresh chicory roots characterised by its mean DP (> 9). 
The Panel considers that the food constituent “native chicory inulin”, a non-fractionated mixture of 
monosaccharides (< 10%), disaccharides, inulin-type fructans and inulin extracted from chicory, with 
a mean DP ≥ 9, is sufficiently characterised in relation to the claimed effect.  
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “improves bowel function”. The target population 
proposed by the applicant is the general population. At the request of EFSA the applicant clarified that 
the claimed effect is “improves bowel function by increasing stool frequency”.  
Constipation is associated with less frequent defecations (i.e. bowel movements, e.g. fewer than three 
per week, reduced faecal bulk and harder stools), which lead to gastrointestinal discomfort and may 
contribute to diseases, such as diverticular disease. More frequent defecations, i.e. bowel movements 
(e.g. through a reduction in transit time, increased faecal bulk, and softer stools) may contribute to the 
maintenance of normal defecation, provided that they do not result in diarrhoea.    
The Panel considers that maintenance of normal defecation by increasing stool frequency (provided 
that it does not result in diarrhoea) is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Caplus, Embase, Medline, and Biosis databases using 
the following search terms: prebiotic or fructan or fructans or FOS or fructooligosaccharide or fructo-
oligosaccharide or oligo-fructose or inulin or inulin-type fructans or oligofructose and bowel habit or 
bowel regularity or bowel function or bowel motor function or bowel movement or large bowel 
function or stool regularity or stool frequency or stool consistency or soft stool or stool weight or stool 
bulk or gut function or gastrointestinal function or constipation or transit or faecal weight or faecal 
bulk or faeces. No limits were given with respect to dates, languages and population subgroups. A 
manual search was also carried out. 
Ten human intervention studies were provided on the effects of “native chicory inulins” or chicory 
inulin on stool frequency. One study was available only as a poster abstract (Isakov et al., 2013). The 
Panel considers that sufficient information was not provided for that study to allow a scientific 
evaluation. Another study was performed with “native chicory inulin” with a mean DP < 9 (Brighenti 
et al., 1999). The Panel considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claim. 
Six of the remaining eight human studies provided reported an increase in stool frequency with the 
consumption of “native chicory inulins” (mean DP > 9) (Gibson et al., 1995; Kleesen et al., 1997; 
Gråsten et al., 2003; Kleesen et al., 2007; Schulz et al., 2012 claimed as proprietary by the applicant) 
or chicory inulin (DP > 9) (Den Hond et al., 2000). In these studies, the doses of “native chicory 
inulin” used ranged from 12 to 40 g/day and the dose of chicory inulin was 15 g/day. In two studies 
(three arms), administration of doses from 5 to 8 g/day did not affect stool frequency (Bouhnik et al., 
2007; Kolida et al., 2007). No adverse effects were reported in any of the studies mentioned above. 
The mean DP of the “native chicory inulin” used in these studies was 9–11. 
The Panel notes that these human intervention studies are very heterogeneous regarding the dose of 
chicory inulin used, the form in which was administered (powder in sachets, in bakery products, 
breakfast cereals, chocolate drinks), the duration of the intervention (from one to four weeks), the 
sample size (4 to 44 subjects), the type of subjects recruited (healthy volunteers, subjects with 
“Native chicory inulin” and maintenance of normal defecation 
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constipations), the age of participants (23 to 76 years) and the study settings (free-living individuals, 
hospitalised subjects, subjects in a metabolic room). The Panel also notes that stool frequency was 
only a secondary outcome in the majority of the studies, and that statistical comparisons between the 
intervention and control groups were not always reported. However, the Panel considers that, taken 
collectively, these studies provide evidence for an increase in stool frequency with the consumption of 
“native chicory inulin” at doses of 12g/day.  
The applicant also provided six human studies showing the non-digestibility of inulin and inulin-type 
fructans in the small intestine and their fermentation in the colon, leading to an increase in total 
bacterial mass (Brighenti et al. 1995, Ellegård et al., 1997; Castiglia-Delavaud et al., 1998; Rumessen 
and Gudmand-Hoyer, 1998; Van Dokkum et al., 1999; Marteau et al., 2011). Seven studies in different 
animal species (dogs, cats, goats, rats, pigs) reported higher stool bulk and softer stools upon ingestion 
of “native chicory inulins” (Delzenne et al., 1995; Diez et al., 1998; Hesta et al., 2001; Kleesen et al., 
2001; Pierce et al., 2005; Verlinden et al., 2006; Kara et al., 2012). The in vitro studies provided 
related to the production of short-chain fatty acids (SCFA) by bacterial degradation of inulin (Wang 
and Gibson, 1993; Rycroft et al., 2001; Timm et al., 2010). 
The Panel notes that inulin and inulin-type fructans in “native chicory inulin” are non-digestible 
carbohydrates which could exert an effect on stool frequency by stimulating bacterial growth in the 
gut and by increasing bacterial cell mass and faecal bulk. The Panel also notes that mono- and 
disaccharides present in “native chicory inulin” in small amounts are unlikely to contribute to the 
claimed effect. 
In weighing the evidence, the Panel took into account that six studies involving 86 subjects 
consistently showed that consumption of at least 12 g/day “native chicory inulin” increases stool 
frequency. The Panel also notes the plausible mechanisms by which inulin and inulin-type fructans in 
“native chicory inulin” could exert the claimed effect. 
The Panel concludes that a cause and effect relationship has been established between the 
consumption of “native chicory inulin”, a non-fractionated mixture of monosaccharides (< 10%), 
disaccharides, inulin-type fructans and inulin extracted from chicory with a mean DP ≥ 9, and 
maintenance of normal defecation by increasing stool frequency. 
The Panel could have reached the conclusion that “native chicory inulin” contributes to the 
maintenance of normal defecation by increasing stool frequency without the data identified as 
proprietary by the applicant (Schulz et al., 2012, unpublished). However, this study (Schulz et al., 
2012, unpublished) was used to establish the conditions of use for this claim. 
4. Panel comments on the proposed wording  
The Panel considers that the following wording reflects the scientific evidence: “Chicory inulin 
contributes to maintenance of normal defecation by increasing stool frequency”.  
5. Conditions and possible restrictions of use  
The Panel considers that, in order to obtain the claimed effect, 12 g of “native chicory inulin” should 
be consumed daily. The target population is the general population.  
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food product, “native chicory inulin”, a non-fractionated mixture of monosaccharides 
(< 10%), disaccharides, inulin-type fructans and inulin extracted from chicory, with a mean 
“Native chicory inulin” and maintenance of normal defecation 
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DP ≥ 9, which is the subject of the health claim, is sufficiently characterised in relation to the 
claimed effect. 
 The claimed effect is “improves bowel function by increasing stool frequency”. The target 
population as proposed by the applicant is the general population. Maintenance of normal 
defecation by increasing stool frequency (provided that it does not result in diarrhoea) is a 
beneficial physiological effect. 
 A cause and effect relationship has been established between the consumption of ”native 
chicory inulin” and maintenance of normal defecation by increasing stool frequency. 
 The following wording reflects the scientific evidence: “Chicory inulin contributes to 
maintenance of normal defecation by increasing stool frequency”. 
 In order to obtain the claimed effect, 12 g of “native chicory inulin” should be consumed 
daily. The target population is the general population.  
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on “native chicory inulin” and maintenance of normal defecation by 
increasing stool frequency pursuant to Article 13.5 of Regulation (EC) No 1924/2006 (Claim serial 
No: 0416_BE). June 2014. Submitted by BENEO-Orafti S.A. 
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ABBREVIATIONS 
DP  degree of polymerisation 
FOS  fructooligosaccharides 
SCFA  short-chain fatty acids 
 
